Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.44 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13126936 | 0.76 | MAPT (0.43) | GAAHTTMAPTLMNAL3MBTL1 | |
| SCHEMBL13111339 | 0.74 | GABRA1 (0.46) | GAAHTTLMNAGABRA1GABRB1 | |
| SCHEMBL13674512 | 0.74 | PTPN1 (0.53) | GAAMAPTLMNAKDM4ENPC1 | |
| SCHEMBL8077322 | 0.73 | GABRA1 (0.72) | GAAHTTLMNAGABRA1GABRB1 | |
| SCHEMBL3732530 | 0.73 | NPC1 (0.69) | GAAMAPTLMNAL3MBTL1KDM4E | |
| SCHEMBL11425674 | 0.72 | MAPT (0.61) | GAAHTTMAPTLMNAL3MBTL1 | |
| SCHEMBL27584559 | 0.71 | GABRA1 (0.53) | GAAHTTLMNAGABRA1GABRB1 | |
| SCHEMBL11847871 | 0.71 | LMNA (0.64) | GAAHTTMAPTLMNAL3MBTL1 | |
| SCHEMBL10757858 | 0.71 | MAPT (0.57) | MAPTLMNAL3MBTL1KDM4ENPC1 | |
| SCHEMBL6318934 | 0.71 | MAPT (0.78) | MAPTLMNAL3MBTL1KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945705-B1 | PHOTOLATENT SYSTEMS | BASF SE (DE) | 2011-10-19 | — | — | EP | disclosed |
| US-7820865-B2 | Photolatent systems | CIBA CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-7820865-B2 | Photolatent systems | CIBA CORPORATION (US) | 2010-10-26 | — | — | US | disclosed |
| US-20090162307-A1 | Photolatent Systems | CIBA CORP. | 2009-06-25 | — | — | US | disclosed |
| US-20090162307-A1 | Photolatent Systems | CIBA CORP. | 2009-06-25 | — | — | US | disclosed |
| EP-1945705-A1 | PHOTOLATENT SYSTEMS | Ciba Holding Inc. (CH) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007054446-A1 | PHOTOLATENT SYSTEMS | CIBA HOLDING INC. (CH) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162307-A1 | Photolatent Systems | CCNT1, CCNT2, C1S | GAA 2162/4885HTT 150/4885MAPT 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.